Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298830 | 1.00 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL3262420 | 1.00 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL16357619 | 0.93 | CDC25A (0.36) | CYP19A1 | |
| SCHEMBL16357100 | 0.90 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL13875472 | 0.87 | CYP19A1 (0.30) | CYP19A1 | |
| SCHEMBL13393072 | 0.86 | — | — | |
| SCHEMBL3301933 | 0.85 | — | — | |
| SCHEMBL13392851 | 0.85 | — | — | |
| SCHEMBL3300963 | 0.85 | — | — | |
| SCHEMBL3261078 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| EP-2073814-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | Bioxell S.p.a. (IT) | 2009-07-01 | — | — | EP | disclosed |
| EP-2063899-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | Bioxell S.p.a. (IT) | 2009-06-03 | — | — | EP | disclosed |
| EP-1879596-A4 | 20-ALKYL, GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL SPA (IT) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008043857-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL SPA (IT) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008034908-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | BIOXELL SPA (IT) | 2008-03-27 | — | — | WO | disclosed |
| EP-1879596-A1 | 20-ALKYL, GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | Bioxell S.p.a. (IT) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006102647-A1 | 20-ALKYL, GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | CYP19A1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.